summary
Introduced
02/07/2025
02/07/2025
In Committee
02/18/2025
02/18/2025
Crossed Over
Passed
Dead
Introduced Session
104th General Assembly
Bill Summary
Amends the Illinois Food, Drug and Cosmetic Act. Provides that any health care practitioner authorized by applicable law to issue prescriptions for Schedule II controlled substances shall, prior to issuing an initial prescription for a Schedule II controlled substance or any other opioid pain reliever during a course of treatment for acute or chronic pain shall discuss with the patient or the patient's parent or guardian, if the patient is under 18 years of age and is not an emancipated minor, the risks associated with the drugs being described. Provides that the discussion required by this provision shall take place before issuing an initial prescription, and again prior to issuing the third prescription during a course of treatment. Provides that the prescribing health care practitioner shall include a note in the patient's medical record that the patient or the patient's parent or guardian, as applicable, has discussed with the practitioner the risks of developing a physical or psychological dependence on the controlled dangerous substance and on alternative treatments that may be available. Provides that these provisions do not apply to prescriptions for a patient who is currently in an active treatment for cancer, receiving hospice care from a licensed hospice or palliative care provider, for a patient who is a resident of a long-term care facility, or to any medications being prescribed for use in the treatment of substance abuse or opioid dependence.
AI Summary
This bill amends the Illinois Food, Drug and Cosmetic Act to require health care practitioners who are authorized to prescribe Schedule II controlled substances or other opioid pain relievers to have a comprehensive discussion with patients (or their parents/guardians if the patient is under 18 and not emancipated) before issuing an initial prescription for treating acute or chronic pain. The mandatory discussion must cover specific key points, including the risks of addiction and overdose associated with opioid drugs, the potential dangers of combining these drugs with alcohol or other central nervous system depressants, the medical necessity of the prescription, and available alternative treatments. This legislation aims to improve patient awareness and informed consent regarding opioid medications, helping patients understand the potential risks and make more educated decisions about their pain management treatment. By mandating these detailed discussions, the bill seeks to address the ongoing opioid crisis by ensuring patients are fully informed about the potential risks and complications of opioid pain medications before beginning treatment.
Sponsors (1)
Last Action
Referred to Rules Committee (on 02/18/2025)
bill text
bill summary
Loading...
bill summary
Loading...
bill summary
| Document Type | Source Location |
|---|---|
| State Bill Page | https://www.ilga.gov/legislation/BillStatus.asp?DocNum=3472&GAID=18&DocTypeID=HB&SessionID=114&GA=104 |
| BillText | https://www.ilga.gov/legislation/104/HB/10400HB3472.htm |
Loading...